Podcast clip: glucose-altering drugs, 17 alpha-estradiol and rapamycin in aging research
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedIn this podcast description, researcher Dr. Rich Miller discusses how acarbose and SGLT2 inhibitors change post-meal glucose patterns, notes that how this slows aging is unknown, and describes sex-specific lifespan findings for 17 alpha-estradiol and rapamycin in mice. [1]
Acarbose and SGLT2 inhibitors such as canagliflozin blunt and prolong post-meal glucose elevation instead of the typical spike-and-crash pattern, per the description. [1]
17 alpha-estradiol extends lifespan in male mice only, with zero effect in females, according to the description. [1]
Rapamycin shows bigger longevity benefits in female mice than males, likely due to sex differences in drug metabolism and blood concentration rather than biology itself, per the description. [1]
Glucose drugs and unexplained aging link
According to the description, Dr. Rich Miller explains that acarbose and SGLT2 inhibitors such as canagliflozin blunt and prolong the rise in blood glucose after meals, rather than producing the usual spike and crash. He says GLP-1 drugs add another layer to this picture. He is candid that no one has pinned down exactly how these glucose-altering drugs translate into slower aging, a question his lab has pursued for the last five years. The description does not report measured outcomes, effect sizes or study designs for these drugs. [1]
17 alpha-estradiol: male mice only
The description says 17 alpha-estradiol, described as a close cousin of estrogen, extends lifespan in male mice only, with zero effect in females. It adds that researchers still do not know which cells or receptors it targets. These are mouse findings as presented in the description; no human lifespan benefit is stated, and the description gives no doses, sample sizes or follow-up periods. [1]
Rapamycin sex difference tied to metabolism
The description states that rapamycin shows bigger longevity benefits in female mice than in males. According to Miller, this likely comes down to sex differences in drug metabolism and blood concentration rather than biology itself. The description presents this as a likely explanation, not a confirmed mechanism, and reports no human data, doses or measured concentrations. [1]
Context & limits
This explainer is based only on the supplied video description; the video and transcript were not reviewed. The description reports no study designs, sample sizes, doses, follow-up periods or effect sizes, and the findings described are in mice, not humans. The description itself notes that the mechanism linking glucose-altering drugs to slower aging is unknown.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
blunt and prolong glucose elevation after meals
extends lifespan in male mice only
bigger longevity benefits in female mice than
About this video
Creator description · original textText language: English
The Science of Skin Podcast · 4 min · Source published: 2026-09-23
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.